Indivior Pharmaceuticals, Inc. INDV Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Product | ||||||
| PERSERIS | $24M+4.3% | $23M-14.8% | $27M-6.9% | $29M-14.7% | $34M-17.1% | |
| Sublingual & other | $222M-1.8% | $226M+3.2% | $219M-4.4% | $229M-4.6% | $240M-3.6% | |
| SUBLOCADE | $912M+6.5% | $856M+7.3% | $798M+3.6% | $770M+2.3% | $753M-0.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Indivior Pharmaceuticals, Inc. break its business down?
- Indivior Pharmaceuticals, Inc. (INDV) reports net revenue by product across 3 parts — PERSERIS, Sublingual & other and SUBLOCADE. Each is extracted from the segment footnotes and tracked over time.
- Where does Indivior Pharmaceuticals, Inc. 's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Indivior Pharmaceuticals, Inc. 's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.